EI
BBIO icon

EAM Investors’s BridgeBio Pharma BBIO Stock Holding History

EAM Investors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-31,374
Closed -$2.33M – 280
2026
Q1 		$2.33M Sell
31,374
-63,832
-67% -$4.63M 0.27% 156
2025
Q4 		$7.28M Sell
95,206
-1,910
-2% -$125K 0.81% 7
2025
Q3 		$4.96M Buy
97,116
+9,950
+11% +$485K 0.57% 61
2025
Q2 		$3.76M Sell
87,166
-26,104
-23% -$949K 0.57% 84
2025
Q1 		$3.92M Buy
+113,270
New +$3.82M 0.68% 49
2024
Q1 		– Sell
-84,679
Closed -$3.42M – 246
2023
Q4 		$3.42M Sell
84,679
-3,488
-4% -$105K 0.61% 83
2023
Q3 		$2.32M Sell
88,167
-66,224
-43% -$1.88M 0.45% 75
2023
Q2 		$2.66M Hold
154,391
– – 0.49% 68
2023
Q1 		$2.56M Buy
+154,391
New +$1.8M 0.5% 65

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

EAM Investors's BBIO Position: Q2 2026 in Review

EAM Investors sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 31,374 shares — an estimated $2.33M sold.

EAM Investors first reported a position in BBIO in Q1 2023 and held it in 9 quarters. The position peaked at $7.28M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • EAM Investors reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
  • EAM Investors sold 31,374 BridgeBio Pharma shares in Q2 2026, an estimated $2.33M.
  • EAM Investors first reported a position in BridgeBio Pharma in Q1 2023 and held it in 9 quarters.
  • EAM Investors's BridgeBio Pharma position peaked at $7.28M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.